

## CARDIO3 BIOSCIENCES APPOINTS VINCENT BRICHARD AS VICE-PRESIDENT IMMUNO-ONCOLOGY

**Mont-Saint-Guibert, Belgium** - Cardio3 BioSciences (C3BS) (*Euronext Brussels and Paris: CARD*), a leader in the discovery and development of regenerative, protective and reconstructive therapies, announces today the appointment of Dr. Vincent Brichard as Vice President immuno-oncology. In this role, Dr. Brichard will lead the newly acquired immuno-oncology technology platform of Cardio3 BioSciences.

Vincent Brichard is a physician by training, specialized in oncology, and holds a PhD in tumor immunology. He started his academic career at the Ludwig Institute for Cancer Research, Brussels Branch, followed by positions at the Institut Curie Cancer Center, Paris, and at the University of Louvain, Brussels. In 2002, he joined GlaxoSmithKline Biologicals, where he led the Cancer Vaccines Business Unit. Until recently, Vincent was the Senior Vice President of the Immunotherapeutics Business Unit, and member of the Vaccines Executive team at GSK Biologicals.

Vincent Brichard will give all support required to build another asset of the Company, by driving, from preclinical towards commercialisation, the development of the products of the immuno-oncology platform.

Vincent Brichard will continue to hold other non-executive positions with other companies, and will continue to bring his expertise to those and other companies in the future.

**Dr. Vincent Brichard, Vice President Immuno-oncology at Cardio3 BioSciences, said:** *"I am pleased to have the opportunity to contribute to the development of Cardio3 BioSciences in the very exciting field of Immuno-Oncology. With the newly acquired CAR T-cells targets, I am confident that Cardio3 BioSciences will have the opportunity to become a major player in this promising field in the near future."*

**Dr. Christian Homsy, CEO of Cardio3 BioSciences, commented:** *"We are extremely pleased to be able to count on Vincent Brichard's expertise to develop our new immuno-oncology franchise. His tremendous experience and closed ties with the pharmaceutical industry will be instrumental to lead our new CAR T-cells technology platform to clinical success in the coming months, and generate significant value creation opportunities to our Company."*

\*\*\* END \*\*\*

For more information, please contact:

**Cardio3 BioSciences**  
Christian Homsy, CEO  
Julie Grade, Corporate Communications Manager

**For Europe: Consilium Strategic Communications**

[www.c3bs.com](http://www.c3bs.com)

Tel. : +32 10 39 41 00

[jgrade@c3bs.com](mailto:jgrade@c3bs.com)

Tel : +44 (0)20 3709 5700



PRESS RELEASE

8 JANUARY 2015

8:15 AM CET

Amber Bielecka, Chris Welsh, Laura Thornton

**For France: NewCap**

Pierre Laurent / Antoine Denry

**For the U.S: The Ruth Group**

Lee Roth (Investors), Kirsten Thomas (Media)

[cardio3@consilium-comms.com](mailto:cardio3@consilium-comms.com)

Tel: + 33(0)1.44.71.94.94

[cardio3@newcap.fr](mailto:cardio3@newcap.fr)

Tel: +1 646 536 7012 / 7014

[lroth@theruthgroup.com](mailto:lroth@theruthgroup.com)

[kthomas@theruthgroup.com](mailto:kthomas@theruthgroup.com)

To subscribe to Cardio3 BioSciences' newsletter, visit [www.c3bs.com](http://www.c3bs.com).

 Follow us on Twitter [@Cardio3Bio](https://twitter.com/Cardio3Bio).

## About Cardio3 BioSciences

Cardio3 BioSciences is a Belgian leading biotechnology company focused on the discovery and development of regenerative and protective therapies. The company was founded in 2007 and is based in the Walloon region of Belgium. Cardio3 BioSciences leverages research collaborations in the US and in Europe with Mayo Clinic and the Cardiovascular Centre Aalst, Belgium.

The Company's lead product candidate C-Cure<sup>®</sup> is an innovative pharmaceutical product that is being developed for heart failure indication. C-Cure<sup>®</sup> consists of a patient's own cells that are harvested from the patient's bone marrow and engineered to become new heart muscle. This process is known as Cardiopoiesis.

Cardio3 BioSciences has also developed C-Cath<sub>ez</sub><sup>®</sup>, the most technologically advanced injection catheter with superior efficiency of delivery of bio therapeutic agents into the myocardium.

Cardio3 BioSciences' shares are listed on Euronext Brussels and Euronext Paris under the ticker symbol CARD.

*C3BS-CQR-1, C-Cure, C-Cath, OnCyte, Cardio3 BioSciences and the Cardio3 BioSciences and C-Cath logos are trademarks or registered trademarks of Cardio3 BioSciences SA, in Belgium, other countries, or both. Mayo Clinic holds equity in Cardio3 BioSciences as a result of intellectual property licensed to the company. In addition to historical facts or statements of current condition, this press release contains forward-looking statements, which reflect our current expectations and projections about future events, and involve certain known and unknown risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. These forward-looking statements are further qualified by important factors, which could cause actual results to differ materially from those in the forward-looking statements, including timely submission and approval of anticipated regulatory filings; the successful initiation and completion of required Phase III studies; additional clinical results validating the use of adult autologous stem cells to treat heart failure; satisfaction of regulatory and other requirements; and actions of regulatory bodies and other governmental authorities.*